Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 117

1.

Outcome analysis of (18)F-fluorodeoxyglucose positron-emission tomography in patients with lung cancer after partial volume correction.

Ohtaka K, Hida Y, Kaga K, Okamoto S, Shiga T, Tamaki N, Muto J, Nakada-Kubota R, Hirano S, Matsui Y.

Anticancer Res. 2013 Nov;33(11):5193-8.

PMID:
24222169
2.

Predictive value of primary fluorine-18 fluorodeoxyglucose standard uptake value for a better choice of systematic nodal dissection or sampling in clinical stage ia non--small-cell lung cancer.

Li X, Zhang H, Xing L, Xu X, Xie P, Ma H, Zhang L, Chen M, Sun X, Xu W, Chen L, Yu J.

Clin Lung Cancer. 2013 Sep;14(5):568-73. doi: 10.1016/j.cllc.2013.02.002. Epub 2013 Jul 5.

PMID:
23835164
3.

Volume-based parameters of (18)F-fluorodeoxyglucose positron emission tomography/computed tomography improve outcome prediction in early-stage non-small cell lung cancer after surgical resection.

Hyun SH, Choi JY, Kim K, Kim J, Shim YM, Um SW, Kim H, Lee KH, Kim BT.

Ann Surg. 2013 Feb;257(2):364-70. doi: 10.1097/SLA.0b013e318262a6ec.

PMID:
22968069
4.
5.

Histological subtypes of lung adenocarcinoma have differential ¹⁸F-fluorodeoxyglucose uptakes on the positron emission tomography/computed tomography scan.

Chiu CH, Yeh YC, Lin KH, Wu YC, Lee YC, Chou TY, Tsai CM.

J Thorac Oncol. 2011 Oct;6(10):1697-703. doi: 10.1097/JTO.0b013e318226b677.

6.

Prognostic value of SUVmax and metabolic tumor volume on 18F-FDG PET/CT in early stage non-small cell lung cancer patients without LN metastasis.

Yoo IeR, Chung SK, Park HL, Choi WH, Kim YK, Lee KY, Wang YP.

Biomed Mater Eng. 2014;24(6):3091-103. doi: 10.3233/BME-141131.

PMID:
25227018
7.

Prognostic value of 18F-FDG uptake on positron emission tomography in patients with pathologic stage I non-small cell lung cancer.

Um SW, Kim H, Koh WJ, Suh GY, Chung MP, Kwon OJ, Choi JY, Han J, Lee KS, Kim J.

J Thorac Oncol. 2009 Nov;4(11):1331-6. doi: 10.1097/JTO.0b013e3181b6be3e.

8.

Prediction of survival by [18F]fluorodeoxyglucose positron emission tomography in patients with locally advanced non-small-cell lung cancer undergoing definitive chemoradiation therapy: results of the ACRIN 6668/RTOG 0235 trial.

Machtay M, Duan F, Siegel BA, Snyder BS, Gorelick JJ, Reddin JS, Munden R, Johnson DW, Wilf LH, DeNittis A, Sherwin N, Cho KH, Kim SK, Videtic G, Neumann DR, Komaki R, Macapinlac H, Bradley JD, Alavi A.

J Clin Oncol. 2013 Oct 20;31(30):3823-30. doi: 10.1200/JCO.2012.47.5947. Epub 2013 Sep 16.

9.

Absence of a relationship between tumor ¹⁸F-fluorodeoxyglucose standardized uptake value and survival in patients treated with definitive radiotherapy for non-small-cell lung cancer.

Lin MY, Wu M, Brennan S, Campeau MP, Binns DS, MacManus M, Solomon B, Hicks RJ, Fisher RJ, Ball DL.

J Thorac Oncol. 2014 Mar;9(3):377-82. doi: 10.1097/JTO.0000000000000096.

10.

Difference in prognostic significance of maximum standardized uptake value on [18F]-fluoro-2-deoxyglucose positron emission tomography between adenocarcinoma and squamous cell carcinoma of the lung.

Tsutani Y, Miyata Y, Misumi K, Ikeda T, Mimura T, Hihara J, Okada M.

Jpn J Clin Oncol. 2011 Jul;41(7):890-6. doi: 10.1093/jjco/hyr062. Epub 2011 May 25.

PMID:
21613306
11.

Prognostic value of pretreatment 18F-fluorodeoxyglucose uptake in patients with cervical cancer treated with definitive chemoradiotherapy.

Onal C, Reyhan M, Parlak C, Guler OC, Oymak E.

Int J Gynecol Cancer. 2013 Jul;23(6):1104-10. doi: 10.1097/IGC.0b013e3182989483.

PMID:
23792605
12.

Prognostic value of FDG uptake in primary inoperable non-small cell lung cancer.

Tong AN, Han SR, Yan P, Gong H, Zhao H, Yao H, Wang YM.

Med Oncol. 2014 Jan;31(1):780. doi: 10.1007/s12032-013-0780-8. Epub 2013 Dec 11.

PMID:
24326983
13.

Maximum standardized uptake value on FDG-PET is a strong predictor of overall and disease-free survival for non-small-cell lung cancer patients after stereotactic body radiotherapy.

Takeda A, Sanuki N, Fujii H, Yokosuka N, Nishimura S, Aoki Y, Oku Y, Ozawa Y, Kunieda E.

J Thorac Oncol. 2014 Jan;9(1):65-73. doi: 10.1097/JTO.0000000000000031.

14.

Revisiting the prognostic value of preoperative (18)F-fluoro-2-deoxyglucose ( (18)F-FDG) positron emission tomography (PET) in early-stage (I & II) non-small cell lung cancers (NSCLC).

Agarwal M, Brahmanday G, Bajaj SK, Ravikrishnan KP, Wong CY.

Eur J Nucl Med Mol Imaging. 2010 Apr;37(4):691-8. doi: 10.1007/s00259-009-1291-x. Epub 2009 Nov 14.

15.

A prediction model for pathologic N2 disease in lung cancer patients with a negative mediastinum by positron emission tomography.

Farjah F, Lou F, Sima C, Rusch VW, Rizk NP.

J Thorac Oncol. 2013 Sep;8(9):1170-80. doi: 10.1097/JTO.0b013e3182992421.

16.

Prognostic value of FDG uptake in early stage non-small cell lung cancer.

Hanin FX, Lonneux M, Cornet J, Noirhomme P, Coulon C, Distexhe J, Poncelet AJ.

Eur J Cardiothorac Surg. 2008 May;33(5):819-23. doi: 10.1016/j.ejcts.2008.02.005.

PMID:
18374589
17.

Use of maximum standardized uptake value on fluorodeoxyglucose positron-emission tomography in predicting lymph node involvement in patients with primary non-small cell lung cancer.

Muto J, Hida Y, Kaga K, Ohtaka K, Okamoto S, Tamaki N, Nakada-Kubota R, Hirano S, Matsui Y.

Anticancer Res. 2014 Feb;34(2):805-10.

PMID:
24511016
18.

Metabolic imaging metrics correlate with survival in early stage lung cancer treated with stereotactic ablative radiotherapy.

Abelson JA, Murphy JD, Trakul N, Bazan JG, Maxim PG, Graves EE, Quon A, Le QT, Diehn M, Loo BW Jr.

Lung Cancer. 2012 Dec;78(3):219-24. doi: 10.1016/j.lungcan.2012.08.016. Epub 2012 Sep 23.

PMID:
23009727
19.

Volume-based parameters measured by using FDG PET/CT in patients with stage I NSCLC treated with stereotactic body radiation therapy: prognostic value.

Satoh Y, Onishi H, Nambu A, Araki T.

Radiology. 2014 Jan;270(1):275-81. doi: 10.1148/radiol.13130652. Epub 2013 Oct 28.

PMID:
24029640
20.

Value of F-18-fluorodeoxyglucose positron emission tomography after induction therapy of locally advanced bronchogenic carcinoma.

Hellwig D, Graeter TP, Ukena D, Georg T, Kirsch CM, Schäfers HJ.

J Thorac Cardiovasc Surg. 2004 Dec;128(6):892-9.

Supplemental Content

Support Center